Clinical Trials in North Carolina

Showing 9001-9020 of 15,496 trials

Evaluating a Messaging Campaign in the United States

NCT04562636

Purpose: To evaluate reactions to and opinions of a messaging campaign. Participants: Participants will be recruited through Prime Panels and will be US-based adults (18 years old and older) who consumed red meat in the past 30 days. Procedures (methods): After completing a screening question about meat consumption, participants will review a consent form. If they select to participate in the study, participants will be randomly assigned to view control messages, red meat-related environment messages, or red meat-related health messages. They will be asked a series of questions about these messages. Participants will also be asked about grocery shopping preferences and standard demographics questions.

ObesityHeart DiseasesCancer

University of North Carolina, Chapel Hill1,244 participantsStarted Sep 2020

Chapel Hill, North Carolina, United States

COMPLETED46 miles

Full-arch Monolithic Zirconia ISFDP Follow up

NCT02931968

This study is designed to recall all patients who have received a full-arch monolithic zirconia implant supported fixed dental prosthesis in the University of North Carolina (UNC) School of Dentistry Graduate Prosthodontic and/or Dental Faculty Practice clinics between January 1, 2008 to September 1, 2015. The main purpose is to evaluate the biological and technical complications associated with this form of prosthetic treatment. Additionally patient centered outcomes will be evaluated.

Edentulous

University of North Carolina, Chapel Hill22 participantsStarted Jan 2017

Chapel Hill, North Carolina, United States

COMPLETEDPhase 357 miles

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

NCT00014222

RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.

Breast Cancer

NCIC Clinical Trials Group2,104 participantsStarted Dec 2000

Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +75 more locations

Evaluating a Messaging Campaign in the United States

Full-arch Monolithic Zirconia ISFDP Follow up

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Find Trials by Condition in North Carolina

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

EVOLVE Short DAPT Study

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Cell-based Assays for Antibody-mediated Transplant Rejection

Losartan to Reverse Sickle Nephropathy

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib